EducationalSymposia-rp
Description
Room: 309 (Level 300)
HEALTHCARE GRIDLOCK BETWEEN VALUE, AFFORDABILITY, AND ACCESS: THE GOOD, THE BAD AND THE UGLY
The dilemma of managing the affordability of an innovative healthcare intervention while reaping its benefits often becomes the rate-limiting step to access. In this session, the panel will discuss good principles of value frameworks, as well as other forms of economic assessments. These considerations can help balance the value of a product with its affordability and ultimately translates to better patient access and improved outcomes.

Moderator: David Harrison, PhD
Director, Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA

Speaker: Diana Brixner, PhD, RPh, FAMCP
Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes, University of Utah, Salt Lake City, UT, USA

Speaker: Sara Carruth, PharmD
Manager in Health Economic and Outcomes, MedImpact Healthcare Systems, San Diego, CA, USA

Speaker: Jeff Dunn, Pharm.D., MBA
Vice President, Magellan RX, Salt Lake City, UT, USA

Amgen
(Sponsored by Amgen)
Tags